Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib improved responses and overall survival compared to standard chemotherapy for patients with metastatic urothelial cancers with FGFR ...
Oct 23, 2023
0
0
They are troubling questions that have researchers across the country stumped—why are more young people being diagnosed with colorectal cancer, and why do some people have worse outcomes than others? It's a topic of particular ...
Sep 20, 2021
0
2
For patients with hormone receptor (HR)-positive HER2-mutant metastatic breast cancer (MBC) with progression on cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy, neratinib + fulvestrant + trastuzumab (N + F + T) is ...
Nov 29, 2023
0
0
A growing number of patients with advanced lung cancer could soon be offered a blood test to help to decide the best treatment for them instead of having to get a tumour sample for analysis. New data from the BFAST trial ...
Sep 30, 2019
0
5
Death rates from prostate cancer are predicted to fall in 2020 in the EU, largely due to better diagnosis and treatment, according to new research published in the leading cancer journal Annals of Oncology today.
Apr 20, 2020
0
2
Targeted therapy in early stages of breast cancer can pave the way for a notable higher success rate, shows a study from the University of Bergen, Norway (UiB).
Apr 20, 2021
0
5
De-escalation approaches in the treatment of women with HER2 positive breast cancer need to be personalised, according to Dr. Carmen Criscitiello, European Institute of Oncology, Milan, Italy. Her comments come on the occasion ...
May 1, 2019
0
3
Early-stage colon cancer patients could benefit in the future from specific genetic tests that forecast their prognosis and help them make the right decision regarding chemotherapy. Two of the biomarkers involved are the ...
Jul 26, 2017
0
0
Immunotherapy can extend the response of some head and neck tumors to treatment, maintaining the anti-tumor effects and preventing them from growing or spreading for longer, a study reports.
Oct 4, 2023
0
1
Results of EORTC trial 10994 appearing in the Annals of Oncology show that pathological complete response after neoadjuvant chemotherapy is an independent predictive factor of favorable clinical outcomes in all molecular ...
Apr 2, 2014
0
0
